|
1
|
DeMaagd G and Philip A: Parkinson's
disease and its management: Part 1: Disease entity, risk factors,
pathophysiology, clinical presentation, and diagnosis. PT.
40:504–532. 2015.
|
|
2
|
Uttara B, Singh AV, Zamboni P and Mahajan
RT: Oxidative stress and neurodegenerative diseases: A review of
upstream and downstream antioxidant therapeutic options. Curr
Neuropharmacol. 7:65–74. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guo C, Sun L, Chen X and Zhang D:
Oxidative stress, mitochondrial damage and neurodegenerative
diseases. Neural Regen Res. 8:2003–2014. 2013.PubMed/NCBI
|
|
4
|
Sarkar S, Raymick J and Imam S:
Neuroprotective and therapeutic strategies against Parkinson's
disease: Recent Perspectives. Int J Mol Sci. 17:172016. View Article : Google Scholar
|
|
5
|
Nayak L and Henchcliffe C: Rasagiline in
treatment of Parkinson's disease. Neuropsychiatr Dis Treat.
4:23–32. 2008.PubMed/NCBI
|
|
6
|
Riederer P and Laux G: MAO-inhibitors in
Parkinson's disease. Exp Neurobiol. 20:1–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bonneh-Barkay D, Ziv N and Finberg JP:
Characterization of the neuroprotective activity of rasagiline in
cerebellar granule cells. Neuropharmacology. 48:406–416. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu D, Johnson C, Johnson S, Tazik S and Ou
XM: The neuroprotective effect of antidepressant drug via
inhibition of TIEG2-MAO B mediated cell death. Drug Discov Ther.
2:289–295. 2008.PubMed/NCBI
|
|
9
|
Zhao Q, Cai D and Bai Y: Selegiline
rescues gait deficits and the loss of dopaminergic neurons in a
subacute MPTP mouse model of Parkinson's disease. Int J Mol Med.
32:883–891. 2013.PubMed/NCBI
|
|
10
|
Hara MR, Thomas B, Cascio MB, Bae BI,
Hester LD, Dawson VL, Dawson TM, Sawa A and Snyder SH:
Neuroprotection by pharmacologic blockade of the GAPDH death
cascade. Proc Natl Acad Sci USA. 103:pp. 3887–3889. 2006;
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maruyama W, Akao Y, Carrillo MC, Kitani K,
Youdium MB and Naoi M: Neuroprotection by propargylamines in
Parkinson's disease: Suppression of apoptosis and induction of
prosurvival genes. Neurotoxicol Teratol. 24:675–682. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lecht S, Haroutiunian S, Hoffman A and
Lazarovici P: Rasagiline - a novel MAO B inhibitor in Parkinson's
disease therapy. Ther Clin Risk Manag. 3:467–474. 2007.PubMed/NCBI
|
|
13
|
Fowler JS, Volkow ND, Logan J, Schlyer DJ,
MacGregor RR, Wang GJ, Wolf AP, Pappas N, Alexoff D and Shea C:
Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's
disease: The degree and reversibility of human brain MAO B
inhibition by Ro 19 6327. Neurology. 43:1984–1992. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Abdanipour A, Tiraihi T and Delshad A:
Trans-differentiation of the adipose tissue-derived stem cells into
neuron-like cells expressing neurotrophins by selegiline. Iran
Biomed J. 15:113–121. 2011.PubMed/NCBI
|
|
15
|
Abdanipour A and Tiraihi T: Induction of
adipose-derived stem cell into motoneuron-like cells using
selegiline as preinducer. Brain Res. 1440:23–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abdanipour A, Sagha M, Noori-Zadeh A,
Pakzad I and Tiraihi T: In vitro study of the long-term cortisol
treatment effects on the growth rate and proliferation of the
neural stem/precursor cells. Neurol Res. 37:117–124. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suzuki S, Namiki J, Shibata S, Mastuzaki Y
and Okano H: The neural stem/progenitor cell marker nestin is
expressed in proliferative endothelial cells, but not in mature
vasculature. J Histochem Cytochem. 58:721–730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gu J, Chi M, Sun X, Wang G, Li M, Liu L
and Li X: Propofol-induced protection of SH-SY5Y cells against
hydrogen peroxide is associated with the HO-1 via the ERK pathway.
Int J Med Sci. 10:599–606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han J, Talorete TP, Yamada P and Isoda H:
Anti-proliferative and apoptotic effects of oleuropein and
hydroxytyrosol on human breast cancer MCF-7 cells. Cytotechnology.
59:45–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Abdanipour A, Noori-Zadeh A, Mesbah-Namin
SA, Bakhtiyari S, Nejatbakhsh R and Anarkooli IJ: Di-(2-ethylhexyl)
phthalate-induced hippocampus-derived neural stem cells
proliferation. Cell J. 19:166–172. 2017.PubMed/NCBI
|
|
21
|
Didenko VV, Ngo H and Baskin DS: Early
necrotic DNA degradation: Presence of blunt-ended DNA breaks, 3′
and 5′ overhangs in apoptosis, but only 5′ overhangs in early
necrosis. Am J Pathol. 162:1571–1578. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan JS, Reed A, Chen F and Stewart CN Jr:
Statistical analysis of real-time PCR data. BMC Bioinformatics.
7:852006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Emerit J, Edeas M and Bricaire F:
Neurodegenerative diseases and oxidative stress. Biomed
Pharmacother. 58:39–46. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ischiropoulos H and Beckman JS: Oxidative
stress and nitration in neurodegeneration: Cause, effect, or
association? J Clin Invest. 111:163–169. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shih JC, Chen K and Ridd MJ: Monoamine
oxidase: From genes to behavior. Annu Rev Neurosci. 22:197–217.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jakubauskiene E, Janaviciute V, Peciuliene
I, Söderkvist P and Kanopka A: G/A polymorphism in intronic
sequence affects the processing of MAO-B gene in patients with
Parkinson disease. FEBS Lett. 586:3698–3704. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Youdim MB, Gross A and Finberg JP:
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent
inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol.
132:500–506. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nagatsu T and Sawada M: Molecular
mechanism of the relation of monoamine oxidase B and its inhibitors
to Parkinson's disease: Possible implications of glial cells. J
Neural Transm Suppl. 71:53–65. 2006. View Article : Google Scholar
|
|
29
|
Magyar K and Szende B: (−)-Deprenyl, a
selective MAO-B inhibitor, with apoptotic and anti-apoptotic
properties. Neurotoxicology. 25:233–242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsao CM, Jhang JG, Chen SJ, Ka SM, Wu TC,
Liaw WJ, Huang HC and Wu CC: Adjuvant potential of selegiline in
attenuating organ dysfunction in septic rats with peritonitis. PLoS
One. 9:e1084552014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dias V, Junn E and Mouradian MM: The role
of oxidative stress in Parkinson's disease. J Parkinsons Dis.
3:461–491. 2013.PubMed/NCBI
|
|
32
|
Chetsawang B, Kooncumchoo P, Govitrapong P
and Ebadi M: 1-Methyl-4-phenyl-pyridinium ion-induced oxidative
stress, c-Jun phosphorylation and DNA fragmentation factor-45
cleavage in SK-N-SH cells are averted by selegiline. Neurochem Int.
53:283–288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Inaba-Hasegawa K, Akao Y, Maruyama W and
Naoi M: Rasagiline and selegiline, inhibitors of type B monoamine
oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. J
Neural Transm (Vienna). 120:435–444. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gillies LA and Kuwana T: Apoptosis
regulation at the mitochondrial outer membrane. J Cell Biochem.
115:632–640. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shacka JJ and Roth KA: Regulation of
neuronal cell death and neurodegeneration by members of the Bcl-2
family: Therapeutic implications. Curr Drug Targets CNS Neurol
Disord. 4:25–39. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schwartz PS and Hockenbery DM:
Bcl-2-related survival proteins. Cell Death Differ. 13:1250–1255.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shimizu S, Konishi A, Kodama T and
Tsujimoto Y: BH4 domain of antiapoptotic Bcl-2 family members
closes voltage-dependent anion channel and inhibits apoptotic
mitochondrial changes and cell death. Proc Natl Acad Sci USA.
97:pp. 3100–3105. 2000; View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Malik JM, Shevtsova Z, Bähr M and Kügler
S: Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL
gene transfer. Mol Ther. 11:373–381. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Offen D, Beart PM, Cheung NS, Pascoe CJ,
Hochman A, Gorodin S, Melamed E, Bernard R and Bernard O:
Transgenic mice expressing human Bcl-2 in their neurons are
resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA. 95:pp.
5789–5794. 1998; View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Natsume A, Mata M, Goss J, Huang S, Wolfe
D, Oligino T, Glorioso J and Fink DJ: Bcl-2 and GDNF delivered by
HSV-mediated gene transfer act additively to protect dopaminergic
neurons from 6-OHDA-induced degeneration. Exp Neurol. 169:231–238.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cao YJ, Shibata T and Rainov NG:
Liposome-mediated transfer of the bcl-2 gene results in
neuroprotection after in vivo transient focal cerebral ischemia in
an animal model. Gene Ther. 9:415–419. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nuydens R, Dispersyn G, Van Den Kieboom G,
de Jong M, Connors R, Ramaekers F, Borgers M and Geerts H: Bcl-2
protects neuronal cells against taxol-induced apoptosis by inducing
multi-nucleation. Apoptosis. 5:335–343. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nuydens R, Dispersyn G, Van Den Keiboom G,
de Jong M, Connors R, Ramaekers F, Borgers M and Geerts H: Bcl-2
protects against apoptosis-related microtubule alterations in
neuronal cells. Apoptosis. 5:43–51. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang J, Liu X, Bhalla K, Kim CN, Ibrado
AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by
Bcl-2: Release of cytochrome c from mitochondria blocked. Science.
275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Naoi M, Maruyama W, Akao Y, Yi H and
Yamaoka Y: Involvement of type A monoamine oxidase in
neurodegeneration: Regulation of mitochondrial signaling leading to
cell death or neuroprotection. J Neural Transm Suppl. 71:67–77.
2006. View Article : Google Scholar
|
|
46
|
Naoi M, Maruyama W and Inaba-Hasegawa K:
Type A and B monoamine oxidase in age-related neurodegenerative
disorders: Their distinct roles in neuronal death and survival.
Curr Top Med Chem. 12:2177–2188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chiou SH, Ku HH, Tsai TH, Lin HL, Chen LH,
Chien CS, Ho LL, Lee CH and Chang YL: Moclobemide upregulated Bcl-2
expression and induced neural stem cell differentiation into
serotoninergic neuron via extracellular-regulated kinase pathway.
Br J Pharmacol. 148:587–598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jiang B, Liang P, Deng G, Tu Z, Liu M and
Xiao X: Increased stability of Bcl-2 in HSP70-mediated protection
against apoptosis induced by oxidative stress. Cell Stress
Chaperones. 16:143–152. 2011. View Article : Google Scholar : PubMed/NCBI
|
